FSHD preclinical testing
Development of FSHD-like models and preclinical testing of novel FSHD therapeutics.
FSHD pathogenic mechanisms
The molecular mechanisms driving FSHD pathology are being identified and are revealing new therapeutic avenues.
FSHD is a spectacular model for investigating epigenetic gene regulation in human development and disease.
Welcome to the Peter and Takako Jones Lab. Our primary research focus is on facioscapulohumeral muscular dystrophy (FSHD). FSHD is the most prevalent muscular dystrophy that affects males and females, children and adults. There are both genetic components and epigenetic aspects that correlate with the highly variable levels of disease severity and progression. Currently there is no cure and there are no ameliorative treatments. We are developing novel therapeutics for FSHD including small molecule inhibition, ncRNAs and CRISPR-based approaches. In addition, we use FSHD as a model to investigate epigenetic mechanisms of gene regulation.
Learn more about the research we do in Nevada on muscular dystrophy and how we are working to develop medical treatments.
About the Jones Lab
The most common muscular dystrophy today is facioscapulohumeral—and we're trying to treat it.
Learn more about our research
The Jones Lab is committed to finding a cure to FSHD, so we communicate with the public about this disease.
Learn about our campaign